Transcription factors and potential therapeutic targets for pulmonary hypertension
Frontiers in Cell and Developmental Biology · 17.03.2023 · 11
DOI: 10.3389/fcell.2023.1132060 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Cell and Developmental Biology, online erschienen am 17.03.2023. Verfasst von Liu Yang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Wuxi School of Medicine, Jiangnan University, Wuxi, China. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 196 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Guangdong Science and Technology Department, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
Pulmonary hypertension (PH) is a refractory and fatal disease characterized by excessive pulmonary arterial cell remodeling. Uncontrolled proliferation and hypertrophy of pulmonary arterial smooth muscle cells (PASMCs), dysfunction of pulmonary arterial endothelial cells (PAECs), and abnormal perivascular infiltration of immune cells result in pulmonary arterial remodeling, followed by increased pulmonary vascular resistance and pulmonary pressure. Although various drugs targeting nitric oxide, endothelin-1 and prostacyclin pathways have been used in clinical settings, the mortality of pulmonary hypertension remains high. Multiple molecular abnormalities have been implicated in pulmonary hypertension, changes in numerous transcription factors have been identified as key regulators in pulmonary hypertension, and a role for pulmonary vascular remodeling has been highlighted. This review consolidates evidence linking transcription factors and their molecular mechanisms, from pulmonary vascular intima PAECs, vascular media PASMCs, and pulmonary arterial adventitia fibroblasts to pulmonary inflammatory cells. These findings will improve the understanding of particularly interactions between transcription factor-mediated cellular signaling pathways and identify novel therapies for pulmonary hypertension.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Wuxi School of Medicine, Jiangnan University, Wuxi, China.
- Department of Vascular & Cardiology, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China.
Förderung
- National Natural Science Foundation of China
- Guangdong Science and Technology Department
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Yang, L., Wan, N., Gong, F., Wang, X., Feng, L., & Liu, G. (2023). Transcription factors and potential therapeutic targets for pulmonary hypertension. Frontiers in Cell and Developmental Biology, 11. https://doi.org/10.3389/fcell.2023.1132060
Vancouver
Yang L, Wan N, Gong F, Wang X, Feng L, Liu G. Transcription factors and potential therapeutic targets for pulmonary hypertension. Frontiers in Cell and Developmental Biology. 2023;11. doi:10.3389/fcell.2023.1132060
BibTeX
@article{Yang2023,
author = {Yang, Liu and Wan, Naifu and Gong, Fanpeng and Wang, Xianfeng and Feng, Lei and Liu, Guizhu},
title = {Transcription factors and potential therapeutic targets for pulmonary hypertension},
journal = {Frontiers in Cell and Developmental Biology},
year = {2023},
volume = {11},
doi = {10.3389/fcell.2023.1132060}
}
EUVIMED